Renée Aguiar-Lucander

Renée Aguiar-Lucander

Algemeen Directeur bij HANSA BIOPHARMA AB

Vermogen: 887 784 $ op 30-09-2026

64 jaar
Health Technology
Commercial Services
Finance

Profiel

Renée Julie Elisabet Aguiar-Lucander is currently Chief Executive Officer at Hansa Biopharma AB since 2025.
Also holds Chairman positions at Simparel, Inc. and Exenta, Inc. Serves as Director at Inventiva SA and Egalet A, Independent Director at AC Immune SA, and Director at Ral Capital Ltd. (United Kingdom), all starting in 2025 or ongoing.
Formerly Chief Executive Officer at Calliditas Therapeutics AB from 2017 to 2025.
Previously held roles including Chairman at EnXray Ltd., Director at SpineVision SAS, ImpactRx, Inc., NsGene A, Onyvax Ltd., Sophion Bioscience A, BioSilta Ltd., Danish BioVenture General Partner ApS, Calliditas Therapeutics France SAS, and SciBase Holding AB. Served as Independent Director at Zyla Life Sciences LLC, MedCap AB, and SciBase Holding AB. Held Independent Non-Executive Director position at Newron Pharmaceuticals SpA from 2006 to 2011.
Non-Executive Director at Pulmagen Therapeutics (Synergy) Ltd. Independent Director at Egalet Ltd. in 2013.
Managing Director-Corporate Finance at Lehman Brothers, Inc. (Milan Branch) in 2003.
Partner at 3i Group Plc and 3i Venture Capital.
Chief Operating Officer & Partner at Omega Fund Management UK LLP.
Education includes an MBA from INSEAD and undergraduate studies at Stockholm School of Economics.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
25-09-2026 197.000 ( 0,19% ) 661 364 $ 30-09-2026
11-06-2026 51.136 ( 0,05% ) 133 976 $ 30-09-2026
01-03-2026 24.700 ( 0,01% ) 92 443 $ 30-09-2026

Actieve functies van Renée Aguiar-Lucander

BedrijvenFunctieBegin
HANSA BIOPHARMA AB Algemeen Directeur 24-04-2025
INVENTIVA Directeur/Bestuurslid 22-05-2025
AC IMMUNE SA Directeur/Bestuurslid 19-06-2025
Ral Capital Ltd. (United Kingdom)
Directeur/Bestuurslid -
Voorzitter -
Voorzitter -
Directeur/Bestuurslid -

Eerdere bekende functies van Renée Aguiar-Lucander

BedrijvenFunctieEinde
CALLIDITAS THERAPEUTICS AB Algemeen Directeur 01-01-2025
ZYLA LIFE SCIENCES Directeur/Bestuurslid 10-06-2015
░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░░░░░
░░ ░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Ervaring van Renée Aguiar-Lucander in detail bekijken

Opleiding van Renée Aguiar-Lucander

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

63

Eerstegraads connecties

29

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit29

Miscellaneous

Health Technology

Commercial Services

Health Technology

Health Technology

Commercial Services

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Finance

Health Technology

Finance

Health Technology

Commercial Services

Health Technology

Omega Fund Management UK LLP

Finance

Health Technology

Health Technology

Technology Services

Commercial Services

Technology Services

Ral Capital Ltd. (United Kingdom)

  1. Beurs
  2. Insiders
  3. Renée Aguiar-Lucander